1. Home
  2. CAPR vs TSLX Comparison

CAPR vs TSLX Comparison

Compare CAPR & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.10

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$16.81

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
TSLX
Founded
2005
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2011
2011

Fundamental Metrics

Financial Performance
Metric
CAPR
TSLX
Price
$26.10
$16.81
Analyst Decision
Strong Buy
Buy
Analyst Count
8
9
Target Price
$44.63
$21.61
AVG Volume (30 Days)
937.2K
764.8K
Earning Date
05-12-2026
05-05-2026
Dividend Yield
N/A
10.82%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.31
$1.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$16.04
52 Week High
$40.37
$25.17

Technical Indicators

Market Signals
Indicator
CAPR
TSLX
Relative Strength Index (RSI) 41.34 46.13
Support Level $25.48 N/A
Resistance Level $30.21 $18.65
Average True Range (ATR) 1.40 0.43
MACD 0.33 0.01
Stochastic Oscillator 22.85 49.67

Price Performance

Historical Comparison
CAPR
TSLX

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: